Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.
BACKGROUND
To analyze the ability of bevacizumab (Avastin) eye drops to inhibit corneal neovascularization.


METHODS
interventional case series involving five patients (age: 42 +/- 14 years).


METHODS
Patients with aggressive corneal neovascularisation not responding to conventional therapy were treated with bevacizumab (Avastin) eye drops (5x/day; 5 mg/ml) for 0.5 to 6 months (mean: 3.6 +/- 2; four patients with limbal stem cell deficiency [three due to chemical burns and one inherited] and one after perforating keratoplasty).


RESULTS
Bevacizumab eye drops were well tolerated without obvious corneal side-effects. All five patients showed a reduction in the neovascularized area (decrease 48 +/- 28%; 13-75%).


CONCLUSIONS
Bevacizumab eye drops seem to inhibit corneal neovascularization without obvious corneal epithelial side-effects.
Bock
Felix
F
Department of Ophthalmology, Friedrich-Alexander University Erlangen-Nürnberg, Schwabachanlage 6, Erlangen, Germany.
König
Yanyan
Y
Kruse
Friedrich
F
Baier
Martin
M
Cursiefen
Claus
C
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009883:Ophthalmic Solutions; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab